Dinowise contains Dienogest. Dinowise uses:
Dienoaest is indicated for the treatment of endometriosis.
|Therapeutic Class:||Female Sex hormones|
|Last Updated:||2020-11-22 18:15:00|
Dinowise contains Dienogest 2.0 Mg. Dinowise doses
Tablet-taking can be started on any day of the menstrual cycle.
The dosage of Dinowise is 2 mg daily without any break, taken preferably at the same time each day with some liquid as needed. Tablet must be taken continuously without regard to vaginal bleeding. When a pack is finished, the next one should be started without interruption.
In the event of missed tablet(s), the woman should take 2 mg only, as soon as she remembers, and should then continue the next day to take the tablet at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by 2 mg.
Increased weight; depressed mood, sleep disorder, nervousness, loss of libido, altered mood; headache, migraine; nausea, abdominal pain or distension, flatulence, vomiting; acne; alopecia; back pain; breast discomfort, ovarian cyst, hot flush, uterine/vaginal bleeding including spotting; asthenic conditions, irritability.
Dinowise is a nortestosterone derivative with no androgenic but rather an antiandrogenic activity of approximately 1/3 of that of cyproterone acetate. Dinowise binds to the progesterone receptor of the human uterus with only 10% of the relative affinity of progesterone. Despite its low affinity to the progesterone receptor, dienogest has a strong progestogenic effect in vivo. Dinowise has no significant androgenic, mineralocorticoid or glucocorticoid activity in vivo.
Dinowise acts on endometriosis by reducing the endogenous production of estradiol and thereby suppressing the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions. Additional properties eg, immunologic and antiangiogenic effects, seem to contribute to the inhibitory action of dienogest on cell proliferation.
Before starting Dinowise treatment, pregnancy must be excluded. During treatment, patients are advised to use nonhormonal methods of contraception (e.g, barrier method) if contraception is required.
As Dinowise is a progestogen-only preparation, it can be assumed that special warnings and special precautions for use of other progestogen-only preparations are also valid for the use of Dinowise .
Changes in Bleeding Pattern: Dinowise treatment affects the menstrual bleeding pattern in the majority of women.
Hepatic Impairment: Dinowise is contraindicated in patients with present or past severe hepatic disease.
Impairment of Fertility: Based on available data, ovulation is inhibited in the majority of patients during treatment with Dinowise. However, Dinowise is not a contraceptive.
If contraception is required, a nonhormonal method should be used.
Progestogens including Dinowise are metabolized mainly by the cytochrome P450 3A4 system . Therefore, inducers or inhibitors of CYP3A4 may affect the progestogen drug metabolism. Known CYP3A4 inhibitors like azole antifungals (e.g, ketoconazole, itraconazole, fluconazole), cimetidine, verapamil, macrolides (e.g, erythromycin, clarithromycin and roxithromycin), diltiazem, protease inhibitors (e.g, ritonavir, saquinavir, indinavir, nelfinavir), antidepressants (e.g, nefazodone, fluvoxamine, fluoxetine) may increase plasma levels of progestogens and result in adverse reactions.
Use in Pregnancy: There are limited data from the use of Dinowise in pregnant women. Animal studies and data from women exposed to Dinowise during pregnancy reveal no special risks on pregnancy, embryonic/fetal development, birth or development after birth for humans. However, Dinowise should not be administered to pregnant women because there is no need to treat endometriosis during pregnancy.
Use in Lactation: Treatment with Dinowise during lactation is not recommended. Physiochemical properties and animal data indicate excretion of Dinowise in breast milk. A decision must be made whether to discontinue breastfeeding or to abstain from Dinowise therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Hypersensitivity to dienogest or to any of the excipients of Dinowise. Dinowise should not be used in the presence of any of the conditions such as, Active venous thromboembolic disorder; arterial and cardiovascular disease, (e.g, myocardial infarction, cerebrovascular accident, ischemic heart disease); diabetes mellitus with vascular involvement; presence or history of severe hepatic disease as long as liver function values have not returned to normal; presence or history of liver tumors (benign or malignant); known or suspected sex hormone-dependent malignancies and undiagnosed vaginal bleeding.
Use in Children: Dinowise is not indicated in children prior to menarche. The safety and efficacy of Dinowise in adolescents (menarche to 18 years) has not yet been established.
Use in the Elderly: There is no relevant indication for the use of Dinowise in the geriatric population.
Acute toxicity studies performed with Dinowise did not indicate a risk of acute adverse effects in case of inadvertent intake of a multiple of the daily therapeutic dose. There is no specific antidote. Dinowise 20-30 mg/day (10-15 times higher dose than in Dinogest) over 24 weeks of use were very well tolerated.
Keep in a cool and dry place. Protect from light. Keep out of the reach of children.
Dinowise Tablet price in India 458.15